Trade

with

NPS Pharmaceuticals Inc
(NASDAQ: NPSP)
AdChoices
29.08
+1.42
+5.13%
After Hours :
27.10
-1.98
-6.81%

Open

27.85

Previous Close

27.66

Volume (Avg)

2.84M (2.09M)

Day's Range

27.41-29.27

52Wk Range

21.60-39.68

Market Cap.

3.10B

Dividend Rate ( Yield )

-

Beta

0.83

Shares Outstanding

106.56M

P/E Ratio (EPS)

1,428.57 (0.02)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 155.59M

    • Net Income

    • -13.50M

    • Market Cap.

    • 3.10B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 1.08

    • PEG (Price/Earnings Growth) Ratio

    • 0.29

    • Beta

    • 0.83

    • Forward P/E

    • 22.57

    • Price/Sales

    • 14.84

    • Price/Book Value

    • 22.83

    • Price/Cash flow

    • -156.25

      • EBITDA

      • 1.25M

      • Return on Capital %

      • 0.74

      • Return on Equity %

      • 1.96

      • Return on Assets %

      • 0.74

      • Book Value/Share

      • 1.21

      • Shares Outstanding

      • 106.56M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 41.75

        • Credit Rating

        • -

        • Analysts

        • 4

        • EPS Estimate

        • 1.21

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 53.80

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 8.75

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 96.04

            • 82.75

            • Pre-Tax Margin

            • 1.32

            • 39.38

            • Net Profit Margin

            • 1.08

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 98.70

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -23.20

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -23.00

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.83

              • 0.76

              • Current Ratio

              • 5.90

              • 2.92

              • Quick Ratio

              • 4.94

              • 2.35

              • Interest Coverage

              • 1.19

              • 38.02

              • Leverage Ratio

              • 2.22

              • 2.21

              • Book Value/Share

              • 1.21

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 1,428.57

                • 243.90

                • P/E Ratio 5-Year High

                • 1,966.30

                • 634.30

                • P/E Ratio 5-Year Low

                • 140.73

                • 124.82

                • Price/Sales Ratio

                • 15.24

                • 9.29

                • Price/Book Value

                • 23.47

                • 8.39

                • Price/Cash Flow Ratio

                • -156.25

                • 49.75

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • 1.96

                    (-)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • 0.74

                    (-11.80)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • 5.24

                    (-)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • 10.13k

                  • 117.08k

                  • Inventory Turnover

                  • 0.26

                  • 1.48

                  • Asset Turnover

                  • 0.68

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -1.50M
                  Operating Margin
                  -0.96
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -156.25
                  Ownership

                  Institutional Ownership

                  97.28%

                  Top 10 Institutions

                  51.99%

                  Mutual Fund Ownership

                  63.76%

                  Float

                  84.51%

                  5% / Insider Ownership

                  1.44%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Growth Company Fund

                  •  

                    7,858,731

                  • 0.00

                  • 7.37

                  • Wells Fargo Advantage Growth Fund

                  •  

                    2,990,750

                  • 0.00

                  • 2.81

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    2,457,213

                  • 0.00

                  • 2.31

                  • First Trust NYSE Arca Biotech Fund

                  •  

                    1,965,396

                  • 0.00

                  • 1.96

                  • Fidelity® Series Growth Company Fund

                  •  

                    1,876,000

                  • 0.00

                  • 1.76

                  • Pictet-Biotech

                  •  

                    1,685,360

                  • -9.04

                  • 1.68

                  • Vanguard Small Cap Index

                  •  

                    1,665,866

                  • -0.13

                  • 1.56

                  • iShares Russell 2000 (AU)

                  •  

                    1,634,245

                  • -0.90

                  • 1.69

                  • Vanguard Total Stock Mkt Idx

                  •  

                    1,557,900

                  • 0.34

                  • 1.46

                  • iShares Nasdaq Biotechnology

                  •  

                    1,387,476

                  • -1.85

                  • 1.44

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity Management and Research Company

                  •  

                    15,595,856

                  • +1.14%

                  • 14.64

                  • Wellington Management Company, LLP

                  •  

                    8,486,193

                  • +3.75%

                  • 7.96

                  • Janus Capital Management LLC

                  •  

                    6,460,150

                  • +5.13%

                  • 6.06

                  • Vanguard Group, Inc.

                  •  

                    5,874,715

                  • +3.19%

                  • 5.51

                  • Wells Capital Management Inc.

                  •  

                    5,542,743

                  • +66.64%

                  • 5.20

                  • BlackRock Fund Advisors

                  •  

                    3,631,075

                  • -4.18%

                  • 3.41

                  • Oak Ridge Investments, LLC

                  •  

                    2,846,527

                  • +1.83%

                  • 2.67

                  • AllianceBernstein LP

                  •  

                    2,751,488

                  • +10.23%

                  • 2.58

                  • State Street Corp

                  •  

                    2,138,056

                  • -6.17%

                  • 2.01

                  • Invesco Advisers, Inc

                  •  

                    2,079,556

                  • +98.33%

                  • 1.95

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Speculative Growth

                  Style

                  Small Growth

                  NPS Pharmaceuticals Inc was incorporated in Utah in 1986 and reincorporated in Delaware in 1992. The Company is a biopharmaceutical company, which is focused on the development of new treatment options for patients with rare gastroin...moretestinal and endocrine disorders and serious unmet medical needs. The Company's clinical programs involve two proprietary therapeutic proteins to restore or replace biological function: GATTEX(tm) (teduglutide) and Natpara® (parathyroid hormone 1-84 [rDNA origin] injection). GATTEX is its analog of GLP-2, a protein involved in the regeneration and repair of the intestinal lining, and is in Phase 3 clinical development for parenteral dependent (PN) short bowel syndrome (SBS). SBS is a highly disabling condition that results from surgical resection, congenital defect or di...moresease-associated loss of absorption and the subsequent inability to maintain fluid, electrolyte, and nutrient balances on a conventional diet. Natpara® is the Company’s recombinant full-length human parathyroid hormone (PTH 1-84) that is in Phase 3 clinical development for hypoparathyroidism, a rare condition in which the body does not maintain normal calcium levels in the blood due to insufficient levels of parathyroid hormone. The Company is currently advancing registration studies for GATTEX and Natpara®. The Company has collaborations or royalty agreements with a number of pharmaceutical companies. ‘NPS, ‘NPS Pharmaceuticals’, ‘GATTEX’, and ‘PREOS’ are the Company’s trademarks. The Company has competitors in both the U.S. and internationally including multi-national pharmaceutical companies, chemical companies, biotech companies, universities and other research organizations. Many of its competitors have drug products that have already been approved or are in development, and operate large, well-funded research and development programs in these fields.lessless

                  Key People

                  Dr. Francois Nader,M.D.

                  CEO/Director/President

                  Peter G. Tombros

                  Chairman of the Board/Director

                  Luke M. Beshar

                  CFO/Chief Accounting Officer/Executive VP

                  Dr. Roger J. Garceau,M.D.,F.A.A.P.

                  Chief Medical Officer/Executive VP

                  Joseph J. Rogus

                  Vice President, Divisional

                  • NPS Pharmaceuticals Inc

                  • 550 Hills Drive 3rd Floor

                  • Bedminster, NJ 07921

                  • USA.Map

                  • Phone: +1 908 450-5300

                  • Fax: +1 908 450-5351

                  • npsp.com

                  Incorporated

                  1986

                  Employees

                  207

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: